This article is more than 5 years old. Information may no longer be current.

MacuLogix raises $5 million in Series C funding

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

MacuLogix has raised $5 million in Series C funding, according to a company press release.

The funding allows the company to continue expanding sales operations for the AdaptDx dark adaptometer across the U.S. and initiate commercial distribution in Europe in 2016, the release said.

“Now we have the opportunity to change the diagnostic paradigm for age-related macular degeneration by equipping eye care professionals with the technology to detect functional impairment at its earliest stages, enabling them to better monitor and manage the growing number of patients with this disease in their care,” John G. Edwards, CEO of MacuLogix, said in the release.

Stephen L. Rose, managing director of Fisk Ventures, which led this round of financing, has joined the board of directors of MacuLogix, according to the press release.